PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026British Journal of Clinical Pharmacology0 citationsOpen Access

Development and validation of a tool assessing adherence to warfarin therapy (TAAW) by Brazilian patients

View Full Paper
CFCarolina Barbosa FerreiraMVMayara Sousa ViannaAPAdriana Silvina Pagano

Key Result

The TAAW tool showed excellent reliability (Cronbach's alpha=0.98, ICC=0.96) and validity (Spearman's rho=0.91) in assessing adherence to warfarin therapy in Brazilian patients.

Key Points

  • To create and validate a multidimensional tool that measures adherence to warfarin therapy among Brazilian patients.
  • Developed a Tool for Assessing Adherence to Warfarin Therapy (TAAW) covering various related aspects.
  • Guided by concept mapping, expert assessments, and pre-testing with participants.
  • Conducted psychometric evaluations including exploratory factor analysis and reliability testing.
  • Out of 35 initial items, 21 were finalized covering warfarin intake, self-care, and health monitoring.
  • TAAW showed excellent internal consistency (Cronbach's alpha = 0.98) and high reliability (Intraclass Correlation Coefficient = 0.96).
  • The tool correlated strongly with therapeutic range time (Spearman's rho = 0.91), confirming its effectiveness in assessing adherence.

Structured PICO

Is the newly developed Tool for Assessing Adherence to Warfarin Therapy (TAAW) a valid and reliable instrument for Brazilian patients?

P
Population
Brazilian patients on warfarin therapy (pre-testing phase included 30 participants)
I
Intervention
Tool for Assessing Adherence to Warfarin Therapy (TAAW), a 21-item multidimensional instrument
O
Outcome
Psychometric validity and reliability of the TAAW tool (including internal consistency, test-retest reliability, and correlation with time in therapeutic range)patient reported

The TAAW is a highly reliable and valid 21-item tool for assessing warfarin adherence in Brazilian patients, correlating strongly with clinical time in therapeutic range.

Abstract

Abstract Aim To develop and validate a multidimensional tool to assess adherence to warfarin therapy by Brazilian patients. Methods A Tool for Assessing Adherence to Warfarin Therapy (TAAW) was designed to encompass warfarin intake and other treatment‐related aspects, including causal and effect items of adherence. The development process included: (i) construction of a concept map; (ii) elaboration of a preliminary version; (iii) expert assessment; (iv) semantic analysis through pre‐testing with 30 participants; and (v) psychometric validation, including exploratory factor analysis, internal consistency, test–retest reliability and hypothesis testing. Results Of the 35 initially drafted items, 14 were discarded and 19 modified, resulting in a final version with 21 items distributed across three dimensions: warfarin intake (n = 10), self‐care associated with warfarin use (n = 7) and health monitoring (n = 4). The TAAW tool demonstrated a unidimensional structure, excellent internal consistency (Cronbach's alpha = 0.98), high test–retest reliability (Intraclass Correlation Coefficient = 0.96) and strong correlation with the time in therapeutic range (Spearman's rho = 0.91), confirming its validity and reliability. Conclusion The validated TAAW is a robust instrument for assessing adherence to warfarin therapy in clinical and research settings. Its comprehensive approach allows for the identification of adherence patterns, enabling healthcare professionals to implement targeted interventions and optimize anticoagulation outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ferreira et al. (2026) studied this question. The TAAW tool showed excellent reliability (Cronbach's alpha=0.98, ICC=0.96) and validity (Spearman's rho=0.91) in assessing adherence to warfarin therapy in Brazilian patients.

synapsesocial.com/papers/698827c90fc35cd7a8846bechttps://doi.org/10.1002/bcp.70467
Ask AI
Helpful
Bookmark
Share
View Full Paper